Antiatherosclerotic effects of statins: LDL versus non-LDL effects

Current Atherosclerosis Reports

Volumn 9, Issue 4, 2007, Pages 281-285

  Selwyn, Andrew P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; RHO KINASE;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEATH; DISEASE MODEL; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; HEART INFARCTION; HUMAN; INFLAMMATION; ISOPRENYLATION; LOW DRUG DOSE; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; STROKE;

ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; RHO-ASSOCIATED KINASES; RISK FACTORS;

EID: 36049003584     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-007-0034-3     Document Type: Review

References (15)

1. Dzau VJ, Antman EM, Black HR, et al.: The Cardiovascular Disease Continuum Validation; clinical evidence of improved outcomes: Part 1: pathophysiology and clinical evidence (risk factors through stable coronary disease). Circulation 2007, 114:2850-2870.
2. Libby P, Ridker PM: Inflammation in atherosclerosis. Circulation 2002, 105:1135-1143.
3. Robinson JG, Smith B, Maheshwari N, et al.: Pleiotropic effects of statins: benefit beyond cholesterol reduction? a meta-regression analysis. J Am Coll Cardiol 2005, 46:1855-1862
4. Tesfamariam B: The effects of HMG-CoA reductase inhibitors on endothelial function. Am J Cardiovasc Drugs 2006, 6:115-120.
5. Ray KR, Cannon CP: The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 2005, 46:1425-1433.
6. Liao J: Rho-kinase: a potential link between hypercholesterolemia and abnormal vascular smooth muscle contraction. Circ Res 2006, 99:238-239.
7. Shimokawa H, Takeshita A: Rho kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biology 2005, 25:1767-1775.
8. Noma K, Oyama N, Liao JK: Physiological role of ROCKS in the cardiovascular system. Am J Physiol Cell Physiol 2006, 290:C661-C666.
9. Nohria A, Grunert M, Rikitake Y, et al.: Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res 2006, 99:1426-1432.
10. Noma K, Goto C, Nishioka K, et al.: Roles of Rho-associated kinase and oxidative stress in the pathogenesis of aortic stiffness. J Am Coll Cardiol 2007, 49:698-705.
11. Rikitake Y, Liao JK: Rho-GT pases, statins, and nitric oxide. Circ Res 2005, 97:1232-1235.
12. Liu PY, Chen JH, Lin LJ, et al.: Increased Rho-kinase (ROCK) activity in a Taiwanese population with metabolic syndrome. J Am Coll Cardiol 2007, 49:1619-1624.
13. Ray KK, Cannon CP, McCabe CH, et al.: Early and late benefits of high dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005, 46:1405-1410.
14. Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Effects of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized control trial. JAMA 2004, 291:1071-1080.
15. Landmesser UF, Bahlman F, Meuller M, et al.: Simvastatin versus exenitide: pleiotropic and lipid lowering effects on endothelial function in humans. Circulation 2005, 111:2356-2363.